<ul>
<li>雷蒙德·詹姆斯被聘为财务顾问</li>
<li>实施裁员</li>
</ul>
<p>纽约，2026 年 1 月 30 日（全球新闻稿）—— IO Biotech（纳斯达克：IOBT），一家开发新型免疫调节、现成的治疗性癌症疫苗的临床阶段生物制药公司，今天宣布已聘请雷蒙德·詹姆斯公司作为独家财务顾问，协助公司进行之前宣布的战略选择探索。</p>
<p>公司还宣布正在实施成本控制和现金节约措施，包括大幅裁减公司员工，以降低运营费用，同时公司探索战略选择。</p>
<p><strong>关于 IO Biotech</strong></p>
<p>IO Biotech 是一家临床阶段的生物制药公司，基于其 T-win®平台开发新型免疫调节、现成的治疗性癌症疫苗。T-win 平台基于一种新颖的癌症疫苗方法，旨在激活 T 细胞以靶向肿瘤细胞和肿瘤微环境中的免疫抑制细胞。IO Biotech 总部位于丹麦哥本哈根，并在美国纽约设有总部。有关更多信息，请访问 www.iobiotech.com。请在 LinkedIn 和 X（@IOBiotech）上关注我们的社交媒体渠道。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据 1933 年证券法第 27A 条及 1934 年证券交易法第 21E 条的修订版的前瞻性声明。前瞻性声明，包括关于战略选择审查的性质、时间或结果，以及公司的财务状况或现金流的声明，基于 IO Biotech 当前的假设和对未来事件和趋势的预期，这些事件和趋势影响或可能影响其业务、战略、运营或财务表现，实际结果和其他事件可能与这些声明中表达或暗示的内容有重大不同，原因包括众多风险和不确定性。前瞻性声明本质上受到风险和不确定性的影响，其中一些无法预测或量化。由于前瞻性声明本质上受到风险和不确定性的影响，您不应将这些前瞻性声明视为未来事件的预测。这些前瞻性声明仅在本声明日期有效，不应被过度依赖。除法律要求的情况外，IO Biotech 不承担更新这些声明的义务，无论是由于任何新信息、未来发展还是其他原因。</p>
<p><strong>公司联系方式：</strong></p>
<p>艾米·沙利文，首席财务官</p>
<p>IO Biotech, Inc.</p>
<p>508-479-3480</p>
<p>asu@iobiotech.com</p>
<p><strong>雷蒙德·詹姆斯联系方式：</strong></p>
<p>布莱恩·格里森，董事总经理</p>
<p>雷蒙德·詹姆斯</p>
<p>(201) 988-5082</p>
<p>brian.gleason@raymondjames.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5qRXlNeU0zTkRBeE5UQTRJekl5TmpFME9ERT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5qRXlNeU0zTkRBeE5UQTRJekl5TmpFME9ERT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OTM0ZDg3N2QtYmY3ZC00Yzk1LWExODctZDUwN2NiNjNiM2U3LTEyNzMwMzEtMjAyNi0wMS0zMC1lbg==/tiny/IO-Biotech.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OTM0ZDg3N2QtYmY3ZC00Yzk1LWExODctZDUwN2NiNjNiM2U3LTEyNzMwMzEtMjAyNi0wMS0zMC1lbg==/tiny/IO-Biotech.png"/></p>

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

IOBT

医药突破 ETF - ALPS

IBBQ

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

IOBTQ

<p>IO Biotech（纳斯达克代码：IOBT）已聘请 Raymond James 作为其独家财务顾问，以探索战略选择。该公司正在实施成本控制措施，包括大幅裁员，以降低运营费用。IO Biotech 专注于基于其 T-win®平台开发免疫调节癌症疫苗。公司总部位于丹麦哥本哈根，在美国纽约设有办公室。关于公司财务状况和战略审查的前瞻性声明面临风险和不确定性</p>

<ul>
<li>Raymond James engaged as financial advisor</li>
<li>Reduction in force implemented</li>
</ul>
<div class="lb-trans"><ul>
<li>雷蒙德·詹姆斯被聘为财务顾问</li>
<li>实施裁员</li>
</ul>
</div><p>NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James &amp; Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives.</p>
<div class="lb-trans"><p>纽约，2026 年 1 月 30 日（全球新闻稿）—— IO Biotech（纳斯达克：IOBT），一家开发新型免疫调节、现成的治疗性癌症疫苗的临床阶段生物制药公司，今天宣布已聘请雷蒙德·詹姆斯公司作为独家财务顾问，协助公司进行之前宣布的战略选择探索。</p>
</div><p>The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company’s workforce, to reduce operating expenses while the company explores strategic alternatives.</p>
<div class="lb-trans"><p>公司还宣布正在实施成本控制和现金节约措施，包括大幅裁减公司员工，以降低运营费用，同时公司探索战略选择。</p>
</div><p><strong>About IO Biotech</strong></p>
<div class="lb-trans"><p><strong>关于 IO Biotech</strong></p>
</div><p>IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York. For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).</p>
<div class="lb-trans"><p>IO Biotech 是一家临床阶段的生物制药公司，基于其 T-win®平台开发新型免疫调节、现成的治疗性癌症疫苗。T-win 平台基于一种新颖的癌症疫苗方法，旨在激活 T 细胞以靶向肿瘤细胞和肿瘤微环境中的免疫抑制细胞。IO Biotech 总部位于丹麦哥本哈根，并在美国纽约设有总部。有关更多信息，请访问 www.iobiotech.com。请在 LinkedIn 和 X（@IOBiotech）上关注我们的社交媒体渠道。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the nature, timing or outcome of a review of strategic alternatives, and the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1933 年证券法第 27A 条及 1934 年证券交易法第 21E 条的修订版的前瞻性声明。前瞻性声明，包括关于战略选择审查的性质、时间或结果，以及公司的财务状况或现金流的声明，基于 IO Biotech 当前的假设和对未来事件和趋势的预期，这些事件和趋势影响或可能影响其业务、战略、运营或财务表现，实际结果和其他事件可能与这些声明中表达或暗示的内容有重大不同，原因包括众多风险和不确定性。前瞻性声明本质上受到风险和不确定性的影响，其中一些无法预测或量化。由于前瞻性声明本质上受到风险和不确定性的影响，您不应将这些前瞻性声明视为未来事件的预测。这些前瞻性声明仅在本声明日期有效，不应被过度依赖。除法律要求的情况外，IO Biotech 不承担更新这些声明的义务，无论是由于任何新信息、未来发展还是其他原因。</p>
</div><p><strong>Company Contact:</strong></p>
<div class="lb-trans"><p><strong>公司联系方式：</strong></p>
</div><p>Amy Sullivan, CFO</p>
<div class="lb-trans"><p>艾米·沙利文，首席财务官</p>
</div><p>IO Biotech, Inc.</p>
<div class="lb-trans"><p>IO Biotech, Inc.</p>
</div><p>508-479-3480</p>
<div class="lb-trans"><p>508-479-3480</p>
</div><p>asu@iobiotech.com</p>
<div class="lb-trans"><p>asu@iobiotech.com</p>
</div><p><strong>Raymond James Contact:</strong></p>
<div class="lb-trans"><p><strong>雷蒙德·詹姆斯联系方式：</strong></p>
</div><p>Brian Gleason, Managing Director</p>
<div class="lb-trans"><p>布莱恩·格里森，董事总经理</p>
</div><p>Raymond James</p>
<div class="lb-trans"><p>雷蒙德·詹姆斯</p>
</div><p>(201) 988-5082</p>
<div class="lb-trans"><p>(201) 988-5082</p>
</div><p>brian.gleason@raymondjames.com</p>
<div class="lb-trans"><p>brian.gleason@raymondjames.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5qRXlNeU0zTkRBeE5UQTRJekl5TmpFME9ERT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY0NjEyMyM3NDAxNTA4IzIyNjE0ODE="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OTM0ZDg3N2QtYmY3ZC00Yzk1LWExODctZDUwN2NiNjNiM2U3LTEyNzMwMzEtMjAyNi0wMS0zMC1lbg==/tiny/IO-Biotech.png" alt="" original-src="https://ml.globenewswire.com/media/OTM0ZDg3N2QtYmY3ZC00Yzk1LWExODctZDUwN2NiNjNiM2U3LTEyNzMwMzEtMjAyNi0wMS0zMC1lbg==/tiny/IO-Biotech.png"/></p>

IO Biotech 发布公司最新动态 | IOBT 股票新闻